


Background

- ❖ The One Health Approach (OHA) involves a collaborative, multisectoral, multidisciplinary framework to address public health challenges and achieve optimal health outcomes.
- ❖ OHA recognizes the interconnection between people, animals, plants, and their shared environment.
- ❖ To enhance pandemic preparedness, the FDA has developed strategies to gather public inputs which can enhance its communication strategies
- ❖ This M-CERSI project amplifies the OHA by augmenting and synergizing different disciplines (e.g., social, and behavioral sciences, machine learning, and artificial intelligence options) with expertise from various FDA centers, offices, and academia to harness narrative COVID-19 unstructured publicly available data.

Methodology

- ❖ Human curation and machine learning techniques were augmented with social and behavioral science methods and input by subject matter experts, across four sequential components.
- ❖ Publicly available data was collected from various FDA input and output sources.
- ❖ We systematically narrowed the scope of inclusion to public comments submitted to Regulations.gov in response to COVID-19 related meetings and dockets.
- ❖ We extracted approximately 140,000 comments using computational methods assisted by the newly available Open GSA Application Programming Interface (API).
- ❖ We preprocessed and analyzed the data to generate insights using a machine learning technique, topic modeling, combined with human curation techniques with subject matter experts.



Conclusions

- ❖ This multidisciplinary research collaboration supports the public health mission and the OHA, by effectively reducing silos and leveraging expertise across the scientific spectrum.
- ❖ This approach can be implemented to advance methods to structure unstructured data (e.g. docket comments) .
- ❖ The next phase of research will apply discovered insights to design focus group sample populations, contrast emerging themes, and develop clear messaging that is responsive to public interests and concerns.


Funding Source

This research was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award [Center of Excellence in Regulatory Science and Innovation cooperative agreement with University of Maryland, U01FD005946] totaling \$698,224 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.

Reference

Regulations.gov API. GSA Open Technology. <https://open.gsa.gov/api/regulationsgov/>. Accessed October 4, 2022.

Contact



Godwin Okoye, email: gokoye@umaryland.edu
University of Maryland School of Pharmacy